10-Year Survival Rate for Melanoma Patients Using Opdivo-Yervoy Combination
Transformative Results for Melanoma Treatment
In a groundbreaking revelation at the European Society for Medical Oncology (ESMO) Congress, Bristol Myers Squibb (BMS) announced that the long-term survival rate for patients with advanced melanoma utilizing the combination therapy of Opdivo and Yervoy stands at an impressive 43% after a decade. This marks a monumental shift from previous survival statistics that reported only about 25% of melanoma patients surviving their first year.
Significant Findings from Long-Term Study
- The median overall survival for patients receiving the combination therapy reached 71.9 months, representing the longest reported survival in a Phase III advanced melanoma trial.
- In a statement, Dana Walker, VP at BMS, emphasized the dramatic changes in prognosis for these patients.
- Among those who received Opdivo and Yervoy together, 64% did not require any subsequent systemic therapy after 10 years.
BMS Collaboration Changes
In addition to these findings, BMS announced a strategic decision to terminate its collaboration with Immatics concerning the bispecific T cell engager IMA401. As the biotech company moves forward, it will not have to refund the $150 million already allocated for this partnership.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.